Lupus Nephritis: Induction and Maintenance Therapy
Induction Therapy
For active Class III or IV lupus nephritis, initiate treatment with mycophenolate mofetil (MMF) or mycophenolic acid (MPA) combined with glucocorticoids as first-line therapy, with consideration of triple therapy (adding belimumab or a calcineurin inhibitor) for high-risk patients. 1
Standard Dual Therapy Options
- MMF/MPA plus glucocorticoids is the preferred initial regimen for most patients with proliferative lupus nephritis 1
Glucocorticoid Dosing Strategy
The 2024 KDIGO guidelines recommend reduced-dose glucocorticoid regimens to minimize toxicity while maintaining efficacy 1:
- Initial pulse therapy: Methylprednisolone 0.25-0.5 g/day IV for up to 3 days (optional, based on severity) 1
- Oral prednisone: Start at 0.3-0.6 mg/kg/day (maximum 40-50 mg), then taper 1
This represents a significant shift from older high-dose protocols (0.8-1.0 mg/kg/day), as emerging evidence suggests lower starting doses may be equally efficacious with fewer adverse effects 1.
Triple Therapy Indications
Consider adding a third agent (belimumab or calcineurin inhibitor) to standard MMF/glucocorticoid therapy in specific high-risk scenarios 1:
- Belimumab addition: Preferred for patients with repeated kidney flares, high risk of progression to kidney failure, or significant extra-renal SLE activity 1, 2
- Calcineurin inhibitor (voclosporin or tacrolimus) addition: Preferred for patients with preserved kidney function and nephrotic-range proteinuria (likely extensive podocyte injury) 1, 3
Alternative Regimens
- High-dose cyclophosphamide (0.5-0.75 g/m² monthly × 6 months): Consider for patients with adverse prognostic factors (nephritic sediment, GFR 25-80 mL/min, crescents/necrosis in >25% of glomeruli) 1
- Intravenous cyclophosphamide: Appropriate for patients with adherence concerns to oral regimens 1
- MMF-based regimen: Preferred for patients at high infertility risk or with moderate-to-high prior cyclophosphamide exposure 1
Maintenance Therapy
After completing induction therapy (typically 3-6 months), transition to maintenance therapy with MMF as the preferred agent, combined with low-dose or no glucocorticoids, for a total treatment duration of at least 36 months. 1
Preferred Maintenance Regimen
- MMF is the recommended maintenance agent 1
- Azathioprine (2 mg/kg/day) is an acceptable alternative for patients who cannot tolerate MMF, lack access to MMF, or are planning pregnancy 1
Glucocorticoid Management During Maintenance
- Taper to the lowest possible dose during maintenance therapy 1
- Target: <7.5 mg/day or discontinuation after maintaining complete clinical renal response for ≥12 months 1
- Continue glucocorticoids only if required for extra-renal lupus manifestations 1
Duration of Therapy
- Total duration of immunosuppression (induction + maintenance): ≥36 months 1
- For patients on triple therapy (belimumab or CNI-based regimens), continuation of the triple regimen through maintenance phase is appropriate 1
- Multitarget maintenance therapy (tacrolimus + MMF + low-dose prednisone) showed low relapse rates (5.47%) and fewer adverse events compared to azathioprine in Asian populations 4
Treatment Goals and Monitoring
Target Outcomes
- Complete clinical response by 12 months: Proteinuria <0.5-0.7 g/24 hours with normal or near-normal GFR 1
- Early improvement markers 1:
- Evidence of proteinuria improvement by 3 months
- At least 50% reduction in proteinuria (partial response) by 6 months
- For nephrotic-range proteinuria at baseline, extend timeframes by 6-12 months
Common Pitfalls
- Premature treatment changes: Avoid switching therapy before adequate trial duration, especially in patients with nephrotic-range proteinuria who may require extended time to respond 1
- Excessive glucocorticoid exposure: The shift toward reduced-dose regimens reflects recognition of long-term glucocorticoid toxicity; avoid prolonged high-dose therapy 1
- Inadequate treatment duration: Stopping immunosuppression before 36 months increases relapse risk 1